The combination of RKIP expression in the heart with kinase inhibitors such as low-dose drug combinations or EDI would allow efficient cytosolic, antiapoptotic, and cardio-safe ERK1/2 signaling while suppressing cancer progression and protecting from pathological cardiac remodeling and heart failure. Here, PEBP1 is linked to cancer.